-

Dexcom Issues Statement on Recent Market Speculation

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today issued the following statement in response to recent media and market speculation:

“Like many companies, Dexcom’s Board and management team regularly review opportunities to enhance stockholder value and create benefits for customers, including through mergers and acquisitions. It is generally our policy not to comment on rumors or speculation, however, in light of recent sustained media and market speculation as well as the upcoming American Diabetes Association conference, we wish to confirm that Dexcom is not in active discussions regarding a merger transaction at this time. We do not intend to comment further on this topic and we assume no obligation to make any further announcement or disclosure should circumstances change.”

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.

Contacts

Investor Relations Contact:
Sean Christensen
Senior Director – Investor Relations and Corporate FP&A
investor-relations@dexcom.com
(858) 200-0200

Media Contact:
James McIntosh
Head of Public Relations
james.mcintosh@dexcom.com
(619) 884-2118

Industry:

DexCom, Inc.

NASDAQ:DXCM
Release Versions
English

Contacts

Investor Relations Contact:
Sean Christensen
Senior Director – Investor Relations and Corporate FP&A
investor-relations@dexcom.com
(858) 200-0200

Media Contact:
James McIntosh
Head of Public Relations
james.mcintosh@dexcom.com
(619) 884-2118

More News From DexCom, Inc.

Dexcom Further Advances Vision of Glucose Biosensing for All

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch of its fully reimagined Stelo app experience in July for Apple iPhone and Android users in the United States.“Glucose matters for everyone and better understanding it can h...

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of...

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association’s Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e...
Back to Newsroom